The U.K.’s National Institute for Health and Care Excellence (NICE) issued a final determination recommending the use of Eylea for the treatment of wet age related macular degeneration. The anti-VEGF compound, marketed by Bayer outside the US, is a recombinant human fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1, specifically purified and formulated for injection into the eye and capable of binding all forms of (VEGF-A) and Placental Growth Factor (PlGF). The drug is priced at £816/EUR953/$1,240 for a 4mg dose which provides a single 2mg/50 microlitre dose.
UK NICE approves Eylea aflibercept for treatment of age-related macular degeneration
- by swdadmin